Lab Member
Dan Shu, Ph.D.
舒丹
Position:
Postdoctoral Fellow(2025)
Email:
shudandddd@163.com
Education:
2025 Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, M.D
2022 Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, M.Med.
2019 Chongqing Medical University, B.Med.
Research Interest:
Construction of breast cancer organoids and their application in tumor immunotherapy
Publication:
Dan Shu#, Meiying Shen, Kang Li 1, Xiaojian Han, Han Li 1, Zhaofu Tan, Yu Wang, Yang Peng, Zhenrong Tang, Chi Qu, Aishun Jin *, Shengchun Liu*. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy.Annals of Medicine. 54:1, 2580-2596. (#co-first author，* co-corresponding)
Li K#, Shu D#, Li H#, Lan A, Zhang W, Tan Z, Huang M, Tomasi ML, Jin A, Yu H*, Shen M*, Liu S*. SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer. Cell Death Dis.2024 Jun 24;15 (6). (#co-first author，* co-corresponding)
Yingkun Xu#, Dan Shu#, Meiying Shen, Qiulin Wu, Yang Peng, Li Liu, Zhenrong Tang, Shun Gao, Yuan Wang, Shengchun Liu *. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. Journal Of Immunology Research 2022, 9412119. (#co-first author，* co-corresponding)
Li, H. #; Li, K.; Shu, D.; Shen, M.; Tan, Z.; Zhang, W.; Pu, D.; Tan, W.; Tang, Z.; Jin, A*, Sheng, L*. MED16 Promotes Tumour Progression and Tamoxifen Sensitivity by Modulating Autophagy through the mTOR Signalling Pathway in ER-Positive Breast Cancer. Life 2022, 12 (10), 1461. (* co-corresponding)
Ailin Lan #, Han Li, Meiying Shen, Daxue Li, Dan Shu, Yang Liu, Haozheng Tang, Kang Li, Yang Peng*, Shengchun Liu*. Association of depressive symptoms and sleep disturbances with survival among US adult cancer survivors. BMC Medincine. 2024 Jun 5;22(1):225. (* co-corresponding)